FindTrial
Sign In

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT02632994
Enrollment
Unknown
Registered
2015-12-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Interventions

DRUGLY2503029

Administered orally.

DRUGLY3023414

Administered orally.

DRUGLY3838915

Administered orally.

DRUGLY3847429

Administered orally.

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.

Exclusion criteria

* Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Countries

United States

Contacts

CONTACTTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
LillyTrials@Lilly.com1-317-615-4559
CONTACTPhysicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
STUDY_DIRECTORCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Eli Lilly and Company

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 26, 2026